Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are at least 18 years old at the time of signing the consent form.
• People who have been confirmed (through tissue or cell testing) to have a type of cancer called B-cell lymphoma.
• People whose doctor has planned for them to receive a standard, FDA-approved cancer treatment called Axicabtagene Ciloleucel (a type of immune cell therapy).
• People who have received, or are currently receiving, certain strong broad-spectrum antibiotics for at least two days within the 6 months before their scheduled treatment. The specific antibiotics that count include carbapenems (such as meropenem, imipenem, or doripenem), anti-pseudomonal antibiotics (such as cefepime, piperacillin-tazobactam, or ceftazidime), or certain anaerobic antibiotics (such as metronidazole, clindamycin, or amoxicillin-sulbactam).
• People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning fully active to able to carry out light activity), assessed within 7 days before signing the consent form.
• People who are willing and able to give written consent to participate (or have a legally authorised representative do so on their behalf).
• People with a sufficient level of infection-fighting white blood cells (above 1,000 per microlitre) at the time of receiving the study treatment.
• People whose liver is functioning well enough, based on standard blood test results within accepted ranges (confirm with trial site for specific values; an exception may apply for people with a condition called Gilbert's syndrome).
• People whose kidneys are functioning well enough, based on an estimated filtration rate above a certain threshold, measured either by a formula or a urine collection test (confirm with trial site for specific values).
• People who are able and willing to use highly effective contraception, starting 30 days before the first study treatment, throughout the trial, and for at least 12 months after treatment ends for women, and 4 months after treatment ends for men. If pregnancy occurs or is suspected during the trial, the treating doctor must be told immediately.

Who may not be able to join:

• People who have had major surgery in the last 4 weeks and have not yet sufficiently recovered from it before starting the study treatment.
• People who have received a live vaccine in the 30 days before the first study treatment. This includes vaccines for measles, mumps, rubella, chickenpox, yellow fever, rabies, BCG, and typhoid. Note: standard injected seasonal flu vaccines are generally allowed, but nasal spray flu vaccines (such as FluMist®) are not.
• People who have been diagnosed with a primary immune deficiency condition (except for IgA deficiency, which does not exclude participation).
• People who have any medical condition, past or current, that the treating doctor believes could interfere with the study results, make full participation unsafe, or is otherwise not in the person's best interest.
• People with known serious psychiatric conditions or substance use disorders that could make it difficult to follow the trial requirements.
• People who are pregnant or currently breastfeeding.
• Women of childbearing age whose pregnancy blood test (taken within 72 hours before joining) comes back positive.
• People with a history of irritable bowel disease or inflammatory bowel disease.
• People who have difficulty swallowing oral medications or who are at risk of inhaling substances into the lungs (for example, due to a neurological condition).

Important: Always verify eligibility with the trial site directly before applying.